Alx oncology reports second quarter 2025 financial results and provides corporate update

– data from aspen-06 trial highlights cd47 expression as a key predictive biomarker of greater response to evorpacept in her2+ gastric cancer; updated data to be presented at a medical conference in q4 2025

ALXO Ratings Summary

ALXO Quant Ranking